QUVIVIQ (daridorexant)
Insomnia Disorder
MarketedCommercial; Pediatric Phase 2 results reported
Key Facts
Indication
Insomnia Disorder
Phase
Marketed
Status
Commercial; Pediatric Phase 2 results reported
Company
About Idorsia
Idorsia's mission is to discover, develop, and commercialize innovative medicines, building on a legacy of scientific excellence from its Actelion origins. Its key achievement is the global commercialization of QUVIVIQ (daridorexant), a dual orexin receptor antagonist for insomnia, alongside the recent approval of TRYVIO/JERAYGO (aprocitentan) for resistant hypertension. The company's strategy is centered on unlocking the full value of its commercial assets, expanding strategic partnerships, advancing a prioritized pipeline, and maintaining financial discipline, all supported by a highly skilled team of approximately 500 employees.
View full company profile